Marqeta, Inc. reports Q1 2026 results on May 7 carrying a contradictory setup: the stock has quietly rallied 13% in a month, yet the analyst community has spent the past six months trimming targets and downgrading ratings.
The short positioning tells a relatively contained story heading into the print. Short interest has climbed to 4.4% of free float — up roughly 13% from early April levels — but the absolute level remains moderate. Cost to borrow is near its cheapest in a month at 0.47%, down 23% from a month ago, and the lending market is far from tight. Options positioning reinforces the calm: the put/call ratio at 0.16 is nearly flat with its 20-day average of 0.163, with a z-score of just -0.23. No defensive hedging spike here. The recent price gain — up 3% on the week, 13% over the month to $4.48 — has not triggered meaningful short-side escalation.
The analyst backdrop is a different conversation. Multiple firms cut targets and ratings in the months following the February results. Morgan Stanley and UBS both trimmed price targets after the Q4 print, dropping to $5.00 and $4.25 respectively. JP Morgan — which still carries an Overweight — brought its target down to $6.00 from $8.00 in February. The consensus now clusters around $5.14, about 15% above the current price, but that modest upside follows a sustained compression in views. The street is not unanimously bearish: JP Morgan's overweight stands out, and the bull case points to Marqeta's first-mover advantage in modern card-issuing infrastructure, strong gross profit growth, and partnerships with , DoorDash, and Klarna. Bears focus on the revenue outlook revision — driven by accounting treatment on a renegotiated platform partnership — and concern that the BNPL vertical faces tougher year-over-year comparisons as the Klarna relationship matures.
One institutional note adds texture. T. Rowe Price holds over 20% of outstanding shares, a concentration that makes institutional flows particularly meaningful. The 90-day insider net position is modestly positive — the Acting CEO received a large equity award in March — though recent director sells around the $4.10–4.47 level are routine and low in significance. EPS momentum over the past 90 days ranks in the 100th percentile, a strong signal on forward-looking estimate revisions, even as the EPS surprise rank (14th percentile) signals the company has historically struggled to beat consensus on the day.
The Q1 print is therefore less a test of whether Marqeta can grow and more a question of whether gross profit guidance holds at levels that justify the recent re-rating — and whether the revenue accounting noise from the platform renegotiation has fully been absorbed by the Street's models.
See the live data behind this article on ORTEX.
Open MQ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
